Immunostimulatory nanoparticle incorporating two immune agonists for the treatment of pancreatic tumors
出版年份 2020 全文链接
标题
Immunostimulatory nanoparticle incorporating two immune agonists for the treatment of pancreatic tumors
作者
关键词
Cancer immunotherapy, Immunostimulatory nanoparticles, Pancreatic cancer, Systemic delivery, STING and TLR4 agonists, Interferon β
出版物
JOURNAL OF CONTROLLED RELEASE
Volume 330, Issue -, Pages 1095-1105
出版商
Elsevier BV
发表日期
2020-11-12
DOI
10.1016/j.jconrel.2020.11.014
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future
- (2020) Eric S Christenson et al. LANCET ONCOLOGY
- Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma
- (2020) Jia-qiao Fan et al. Molecular Cancer
- Recent insights into the biology of pancreatic cancer
- (2020) Wantong Yao et al. EBioMedicine
- TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer
- (2019) Davide Melisi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Anti–CTLA‐4 synergizes with dendritic cell–targeted vaccine to promote IL‐3–dependent CD4 + effector T cell infiltration into murine pancreatic tumors
- (2019) Neeha Zaidi et al. Annals of the New York Academy of Sciences
- Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features
- (2019) Eva Karamitopoulou BRITISH JOURNAL OF CANCER
- Immune checkpoint protein VISTA regulates antitumor immunity by controlling myeloid cell-mediated inflammation and immunosuppression
- (2019) Wenwen Xu et al. Cancer Immunology Research
- Nanoparticle encapsulation of synergistic immune agonists enables systemic co-delivery to tumor sites and interferon β-driven anti-tumor immunity
- (2019) Prabhani U. Atukorale et al. CANCER RESEARCH
- Stromal barriers to nanomedicine penetration in the pancreatic tumor microenvironment
- (2018) Hiroyoshi Y. Tanaka et al. CANCER SCIENCE
- Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy
- (2018) Derek J. Erstad et al. Disease Models & Mechanisms
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
- (2018) Jun Gong et al. Journal for ImmunoTherapy of Cancer
- Tumor microenvironment participates in metastasis of pancreatic cancer
- (2018) Bo Ren et al. Molecular Cancer
- Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options
- (2018) Derya Kabacaoglu et al. Frontiers in Immunology
- Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
- (2017) Vinod P. Balachandran et al. NATURE
- Crosstalk between Regulatory T Cells and Tumor-Associated Dendritic Cells Negates Anti-tumor Immunity in Pancreatic Cancer
- (2017) Jung-Eun Jang et al. Cell Reports
- Type I Interferons and Natural Killer Cell Regulation in Cancer
- (2017) Lena Müller et al. Frontiers in Immunology
- Myeloid-derived suppressor cells and their role in pancreatic cancer
- (2016) M Pergamo et al. CANCER GENE THERAPY
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Inflammatory features of pancreatic cancer highlighted by monocytes/macrophages and CD4+ T cells with clinical impact
- (2015) Takuya Komura et al. CANCER SCIENCE
- Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
- (2015) A. Patnaik et al. CLINICAL CANCER RESEARCH
- Nanoparticulate STING agonists are potent lymph node–targeted vaccine adjuvants
- (2015) Melissa C. Hanson et al. JOURNAL OF CLINICAL INVESTIGATION
- PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors
- (2015) Kevin C. Soares et al. JOURNAL OF IMMUNOTHERAPY
- STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity
- (2015) Olivier Demaria et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade
- (2015) Juan Fu et al. Science Translational Medicine
- Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity
- (2015) Leticia Corrales et al. Cell Reports
- Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease
- (2014) Joseph Markowitz et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A comparative study of the effects of inhibitory cytokines on human natural killer cells and the mechanistic features of transforming growth factor-beta
- (2014) Hae mi Lee et al. CELLULAR IMMUNOLOGY
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Recent progress in pancreatic cancer
- (2013) Christopher L. Wolfgang et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Neuroblastoma-Derived TGF- 1 Modulates the Chemokine Receptor Repertoire of Human Resting NK Cells
- (2013) R. Castriconi et al. JOURNAL OF IMMUNOLOGY
- Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer
- (2013) Dung T. Le et al. JOURNAL OF IMMUNOTHERAPY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pancreatic Tumors and Immature Immunosuppressive Myeloid Cells in Blood and Spleen: Role of Inhibitory Co-Stimulatory Molecules PDL1 and CTLA4. An In Vivo and In Vitro Study
- (2013) Daniela Basso et al. PLoS One
- Evidence for cyclic diguanylate as a vaccine adjuvant with novel immunostimulatory activities
- (2012) Peter M. Gray et al. CELLULAR IMMUNOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Type I interferon response and innate immune sensing of cancer
- (2012) Mercedes B. Fuertes et al. TRENDS IN IMMUNOLOGY
- Direct Effects of Type I Interferons on Cells of the Immune System
- (2011) S. Hervas-Stubbs et al. CLINICAL CANCER RESEARCH
- Host type I IFN signals are required for antitumor CD8+T cell responses through CD8α+dendritic cells
- (2011) Mercedes B. Fuertes et al. JOURNAL OF EXPERIMENTAL MEDICINE
- STING is a direct innate immune sensor of cyclic di-GMP
- (2011) Dara L. Burdette et al. NATURE
- Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
- (2011) H. Cabral et al. Nature Nanotechnology
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Significance of M2-Polarized Tumor-Associated Macrophage in Pancreatic Cancer
- (2009) Hiroshi Kurahara et al. JOURNAL OF SURGICAL RESEARCH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started